BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/18/2026 10:29:14 AM | Browse: 1 | Download: 0
 |
Received |
|
2025-12-01 01:32 |
|
Peer-Review Started |
|
2025-12-03 09:10 |
|
First Decision by Editorial Office Director |
|
2026-01-15 07:29 |
|
Return for Revision |
|
2026-01-15 07:29 |
|
Revised |
|
2026-01-24 05:28 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-02-12 02:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-12 11:56 |
|
Articles in Press |
|
2026-02-12 11:56 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-04-24 05:40 |
|
Publish the Manuscript Online |
|
2026-05-18 10:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Missing mechanistic data and small inflammatory bowel disease cohorts: Key barriers in ustekinumab switching
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Qin-Jian Wang, Zheng Zhu and Guang-Rong Lu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Wenzhou Science and Technology Bureau |
No. Y20240207 |
|
| Corresponding Author |
Guang-Rong Lu, Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, No. 109 Xueyuan Western Road, Wenzhou 325000, Zhejiang Province, China. 290636246@qq.com |
| Key Words |
Inflammatory bowel disease; Ustekinumab; Biosimilar switching; Therapeutic drug monitoring; Treat-to-target strategy; Nocebo effect; Shared decision-making |
| Core Tip |
Kritzinger et al report high treatment persistence and stable clinical outcomes after non-medical switching from originator ustekinumab to its biosimilar in inflammatory bowel disease. While reassuring, the findings derive from a cohort of long-term, stable responders and lack systematic evaluation of objective endpoints such as endoscopic healing. These limitations restrict generalizability to higher-risk patients – those with active or partially controlled disease – at the time of switch. Future studies must incorporate treat-to-target endpoints and focus on vulnerable subgroups to guide individualized biosimilar conversion strategies in real-world practice. |
| Publish Date |
2026-05-18 10:29 |
| Citation |
Wang QJ, Zhu Z, Lu GR. Letter to the Editor: Missing mechanistic data and small inflammatory bowel disease cohorts: Key barriers in ustekinumab switching. World J Gastroenterol 2026; 32(19): 117160 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i19/117160.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i19.117160 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
